STOCKHOLM, Oct. 27, 2023 /PRNewswire/ — Updated data show that the combination fostrox + Lenvima® provides improved clinical efficacy compared to Lenvima study data alone in second-line HCC July – September Financial summary for the quarter Net turnover amounted to SEK 0.8 (1.1) million….
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.